Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) was up 12.7% during mid-day trading on Monday . The stock traded as high as $0.65 and last traded at $0.62. Approximately 41,154 shares changed hands during mid-day trading, a decline of 12% from the average daily volume of 46,850 shares. The stock had previously closed at $0.55.
Bluejay Diagnostics Stock Performance
The company has a 50 day moving average of $0.76 and a 200 day moving average of $1.90. The stock has a market capitalization of $1.67 million, a price-to-earnings ratio of -0.07 and a beta of 0.85.
Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) last announced its quarterly earnings results on Thursday, March 28th. The company reported ($1.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($1.10).
Hedge Funds Weigh In On Bluejay Diagnostics
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Read More
- Five stocks we like better than Bluejay Diagnostics
- 3 Ways To Invest In Coffee, Other Than Drinking It
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Merger or Not, Albertson’s Companies is a Good Buy
- Insider Buying Explained: What Investors Need to Know
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.